SGLT2 inhibitors and GLP-1 receptor agonists reshaped cardiovascular and renal medicine, while the statin trials remain the backbone of prevention. This page maps the trials a clinician needs across cardiovascular, heart-failure, and kidney outcomes. Each link opens a concise PICO summary with expert commentary.
Statins & lipid lowering
- 4S — simvastatin in secondary prevention; the trial that settled the safety debate.
- Heart Protection Study — benefit across all high-risk patients regardless of baseline LDL.
- WOSCOPS — statins in primary prevention.
- CARDS — atorvastatin in type 2 diabetes; risk, not LDL, drives treatment.
SGLT2 inhibitors — cardiovascular & heart failure
GLP-1 receptor agonists — cardiovascular
Cardio-renal protection
Blood pressure & multifactorial risk
Browse every summary
Cardiovascular Outcomes ·
Heart Failure & Renal ·
Lipids & Statins — or see the GLP-1 and SGLT2 trial guides.
Hormone Insight summaries are reviewed by a practicing endocrinologist and are for healthcare professionals. They summarise published evidence and do not constitute medical advice. See our Editorial Guidelines.